Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nonviral methods for siRNA delivery.

Literature DB >> 19115957

Nonviral methods for siRNA delivery.

Abstract

RNA interference (RNAi) as a mechanism to selectively degrade mRNA (mRNA) expression has emerged as a potential novel approach for drug target validation and the study of functional genomics. Small interfering RNAs (siRNA) therapeutics has developed rapidly and already there are clinical trials ongoing or planned. Although other challenges remain, delivery strategies for siRNA become the main hurdle that must be resolved prior to the full-scale clinical development of siRNA therapeutics. This review provides an overview of the current delivery strategies for synthetic siRNA, focusing on the targeted, self-assembled nanoparticles which show potential to become a useful and efficient tool in cancer therapy.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
RNA, Small Interfering

Year: 2009 PMID： 19115957 PMCID： PMC2692493 DOI： 10.1021/mp800134q

Source DB: PubMed Journal: Mol Pharm ISSN： 1543-8384 Impact factor: 4.939

95 in total

Review 1. Strategies for silencing human disease using RNA interference.

Authors: Daniel H Kim; John J Rossi
Journal: Nat Rev Genet Date: 2007-03 Impact factor: 53.242

2. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Authors: Udit N Verma; Rama M Surabhi; Aurelia Schmaltieg; Carlos Becerra; Richard B Gaynor
Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531

3. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors: James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal: Nat Biotechnol Date: 2006-06-25 Impact factor: 54.908

4. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors: Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal: Nature Date: 2004-11-11 Impact factor: 49.962

Review 5. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors: Shuang Liu
Journal: Mol Pharm Date: 2006 Sep-Oct Impact factor: 4.939

Review 6. Therapeutic potential of RNA interference against cancer.

Authors: Fumitaka Takeshita; Takahiro Ochiya
Journal: Cancer Sci Date: 2006-08 Impact factor: 6.716

7. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.

Authors: Hiroshi Nakamura; Shahid S Siddiqui; Xiang Shen; Asrar B Malik; Jose S Pulido; Nalin M Kumar; Beatrice Y J T Yue
Journal: Mol Vis Date: 2004-10-04 Impact factor: 2.367

8. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors: Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal: Nat Med Date: 2005-08-21 Impact factor: 53.440

Review 9. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.

Authors: Frank Y Xie; Martin C Woodle; Patrick Y Lu
Journal: Drug Discov Today Date: 2006-01 Impact factor: 7.851

Review 10. Interfering with disease: a progress report on siRNA-based therapeutics.

Authors: Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal: Nat Rev Drug Discov Date: 2007-06 Impact factor: 84.694

58 in total

1. Enzyme-synthesized poly(amine-co-esters) as nonviral vectors for gene delivery.

Authors: Jie Liu; Zhaozhong Jiang; Jiangbing Zhou; Shengmin Zhang; W Mark Saltzman
Journal: J Biomed Mater Res A Date: 2010-12-09 Impact factor: 4.396

Review 2. Effect of surface properties on liposomal siRNA delivery.

Authors: Yuqiong Xia; Jie Tian; Xiaoyuan Chen
Journal: Biomaterials Date: 2015-12-02 Impact factor: 12.479

3. Highlighting the role of polymer length, carbohydrate size, and nucleic acid type in potency of glycopolycation agents for pDNA and siRNA delivery.

Authors: Lian Xue; Nilesh P Ingle; Theresa M Reineke
Journal: Biomacromolecules Date: 2013-10-16 Impact factor: 6.988

Nonviral methods for siRNA delivery.

Review 1. Strategies for silencing human disease using RNA interference.

2. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

3. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

4. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Review 5. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Review 6. Therapeutic potential of RNA interference against cancer.

7. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.

8. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Review 9. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.

Review 10. Interfering with disease: a progress report on siRNA-based therapeutics.

1. Enzyme-synthesized poly(amine-co-esters) as nonviral vectors for gene delivery.

Review 2. Effect of surface properties on liposomal siRNA delivery.

3. Highlighting the role of polymer length, carbohydrate size, and nucleic acid type in potency of glycopolycation agents for pDNA and siRNA delivery.

4. Sustained local delivery of siRNA from an injectable scaffold.

5. Polyplex-induced cytosolic nuclease activation leads to differential transgene expression.

Review 6. Lipidic systems for in vivo siRNA delivery.

Review 7. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

8. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery.

9. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Review 10. Lipid-based vectors for siRNA delivery.